Tekmira Pharmaceuticals Corporation Roller Coaster Jumps Then Drops

Mark Melin

Published onAugust 12, 2014

Updated on May 13, 2021

Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) (TSE:TKM), a stock ValueWalk highlighted on Thursday for its Ebola treatments, is now trading down on the day after seeing significant gains Friday and Monday.

Table of Contents

Tekmira’s stock down on on FDA’s restrictions on its Ebola treatments

Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) (TSE:TKM) is down $4.80 today, trading near $19 per share, after taking off on news regarding its Ebola treatments. After closing at $14.37 on Thursday, the stock rocketed to $20.70 on Friday and $23.80 on Monday. The stock took off Thursday after the close of trading on an FDA announcement that released restrictions on the firm’s Ebola treatments.

ValueWalk...

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article

Already a member? Log in here

Mark Melin

Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.

Tekmira Pharmaceuticals Corporation Roller Coaster Jumps Then Drops

Tekmira’s stock down on on FDA’s restrictions on its Ebola treatments

Login required to continue reading.

Get Your Business News